Sirtex Medical, a leading manufacturer of interventional treatment solutions, has announced the commercial availability of the LAVA liquid embolic system, the first and only liquid embolic approved for the treatment of peripheral vascular haemorrhage.
LAVA provides volume and viscosity options that optimise the flexibility needed to treat patients with controlled target vessel occlusion. The product’s 2ml and 6ml options are optimised for the peripheral vasculature, and its viscosity options allow for the distal embolization of small vessels that may be inaccessible via other embolics.
“This product’s ability to maximize the packing density within the target vessel is incredibly important, as it allows us to minimise the likelihood of a future recurrence or restoration of vessel patency,” said Gary Siskin (Albany Medical Center, Albany, USA).
In a study of the LAVA liquid embolic system for the embolic treatment of arterial haemorrhage in peripheral vasculature, the product met both the primary safety and effectiveness endpoints, with 100% of patients experiencing no major adverse events in 30 days and 94% of lesions meeting clinical success in 30 days.
“The trial was an incredible success. Our goal was to achieve 70% efficacy for the existing data and outcomes, but we were able to achieve 94% efficacy,” said Bulent Arslan (Rush Medical College, Chicago, USA) . “I am overjoyed that it is now available for all of our patients.”
“The approval and availability of LAVA is especially meaningful to our team because it is addressing previously unmet needs in vascular medicine, with the potential to create significant impact on patients’ lives,” said Matt Schmidt, chief commercial officer of Sirtex. “We are delighted to expand our Sirtex product portfolio with this treatment milestone that directly furthers our mission to improve the quality and longevity of patient lives through innovative medical solutions, and we thank everyone who played a role to achieve it.”
